CAPRELSA

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States

Active ingredients

The drug CAPRELSA contains one active pharmaceutical ingredient (API):

1 Vandetanib
UNII YO460OQ37K - VANDETANIB

Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2 also known as kinase insert domain containing receptor [KDR]), epidermal growth factor receptor (EGFR) and RET tyrosine kinases. Vandetanib is also a sub-micromolar inhibitor of vascular endothelial receptor-3 tyrosine kinase. Vandetanib inhibits VEGF-stimulated endothelial cell migration, proliferation, survival and new blood vessel formation in in vitro models of angiogenesis. In addition, vandetanib inhibits epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase in tumour cells and endothelial cells.

Read about Vandetanib

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
CAPRELSA Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01EX04 Vandetanib L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 502313020022501, 502313020022601, 576720050064717, 576720050064817
Country: CA Health Products and Food Branch Identifier(s): 02378582, 02378590
Country: EE Ravimiamet Identifier(s): 1556759, 1556760
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 11749001, 11749002
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 416002, 468773
Country: FR Base de données publique des médicaments Identifier(s): 65808531, 69269825
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 203587, 203590
Country: HK Department of Health Drug Office Identifier(s): 62086, 62087
Country: IE Health Products Regulatory Authority Identifier(s): 88786, 88787
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7139
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291041F1029
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1065206, 1065207
Country: NL Z-Index G-Standaard, PRK Identifier(s): 101516, 101524
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100267875, 100267881
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W62995001, W62996001
Country: US FDA, National Drug Code Identifier(s): 58468-7820, 58468-7840

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.